Phase II study of S-1 monotherapy in patients with previously treated, advanced non-small-cell lung cancer

[11] Shepherd FA(2000)Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy J Clin Oncol 18 2095-2103

[12] Fossella FV(2005)Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 123-132

[13] Pereira JR(1996)Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators Anticancer Drugs 7 548-557

[14] De Marinis F(1993)Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats Cancer Res 53 4004-4009

[15] von Pawel J(2011)Phase II study of S-1 monotherapy in platinum-refractory, advanced non-small cell lung cancer Lung Cancer 74 85-88

[16] Gatzemeier U(1984)Thymidylate synthetase inhibition in malignant tumors and normal liver of patients given intravenous 5-fluorouracil Cancer Res 44 4144-4150

[17] Tsao TC(2007)Epidermal growth factor receptor mutation status and adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung J Clin Oncol 25 3952-3957

[18] Pless M(1987)Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts Jpn J Cancer Res 78 748-755

[19] Muller T(2009)A phase II study of S-1 monotherapy as second-line treatment for advanced non-small cell lung cancer Cancer Chemother Pharmacol 64 1181-1185

[20] Lim HL(2005)Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer Br J Cancer 93 884-889

[11] Shepherd FA(2000)Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy J Clin Oncol 18 2095-2103

[12] Fossella FV(2005)Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 123-132

[13] Pereira JR(1996)Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators Anticancer Drugs 7 548-557

[14] De Marinis F(1993)Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats Cancer Res 53 4004-4009

[15] von Pawel J(2011)Phase II study of S-1 monotherapy in platinum-refractory, advanced non-small cell lung cancer Lung Cancer 74 85-88

[16] Gatzemeier U(1984)Thymidylate synthetase inhibition in malignant tumors and normal liver of patients given intravenous 5-fluorouracil Cancer Res 44 4144-4150

[17] Tsao TC(2007)Epidermal growth factor receptor mutation status and adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung J Clin Oncol 25 3952-3957

[18] Pless M(1987)Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts Jpn J Cancer Res 78 748-755

[19] Muller T(2009)A phase II study of S-1 monotherapy as second-line treatment for advanced non-small cell lung cancer Cancer Chemother Pharmacol 64 1181-1185

[20] Lim HL(2005)Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer Br J Cancer 93 884-889